Entourage Advisory Board Member Prof. Schönrich. Interviewed. On the spread of the coronavirus.

Munich, 13 March 2020.

The leading virologist and entourage advisory board member Prof. Dr. Günther Schönrich gives an assessment of the current situation of coronavirus in Germany and Europe.

In an interview with Deutsche Welle, the leading virologist and entourage advisor Prof. Dr. Günther Schönrich gives his assessment of the situation of the coronavirus in Germany and Europe.
In his view, the peak of the epidemic has not yet been reached. It will gain momentum in the coming weeks. He therefore considers it necessary to take the appropriate measures to stop the spread of the virus. In this way, time could be gained to develop a drug that would help to stop the spread of the virus in the human organism.
In the coming weeks, Entourage will keep you informed about the latest developments on coronavirus by Prof. Schönrich.

Short Profile Prof. Dr. Günther Schönrich.

Prof. Dr. med. Günther Schönrich studied Medicine and Philosophy at Albert Ludwig University in Freiburg and graduated in 1985 with a PhD in Medicine, majoring in Cardiology. He completed his post-doc at the Institute of Immunology and Genetics, German Cancer Research Centre in Heidelberg. Mr Schönrich has in-depth expertise in the field of microbiology, virology, infection epidemiology and virus immunology. Since 2006, Mr Schönrich has been Deputy Director of the Institute for Virology (CCM) at the the Charité Universitätsmedizin Berlin.

Short Profile Entourage.

Entourage is a management and personnel consultancy focusing on pharmaceuticals, medical technology and health care. The company, which is based in Munich and Basel, recruits experts for the leading life science companies in the DACH region by placing permanent scientific employees and consultants. With Project Consultants, Entourage implements projects for its clients via highly qualified temporary employment agencies and work contracts. With the Entourage Task Force (ETF), Entourage bundles selected interim managers and management consultants into a top-class consulting unit that implements pharmaceutical and medical technology solution scenarios in consulting projects on an interdisciplinary basis.